You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Biowaivers WHO perspectives
- In: Regulatory harmonisation: Successes and challenges along the pathway to regulatory convergence on Tuesday, 2 September 2025, 11:00-12:30
- At: Copenhagen (Denmark) (2025)
- Type: Presentation
- By: GWAZA, Luther
- Abstract:
Biowaivers play a critical role in accelerating access to quality-assured medicines by reducing the need for in vivo bioequivalence studies when scientifically justified. The World Health Organization (WHO) has issued guidelines on both Biopharmaceutics Classification System (BCS)-based biowaivers and biowaivers for additional strengths, in line..
The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026